Search Results for: acasti

Delays at Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) have Echelon Wealth Partners analyst Douglas Loe lowering his price target … [Read more...] about Acasti Pharma has price target cut at Echelon

Disappointing results for its lead product candidate CaPre have led Mackie research capital analyst André Uddin to place Acasti Pharma (Acasti Pharma … [Read more...] about Acasti Pharma placed under review by Mackie Research Capital

Quebec-based omega-3 drug developer Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) is keeping its "Top Pick" status from Echelon … [Read more...] about Acasti Pharma keeps “Top Pick” Status at Echelon for 2020

Biopharm company Acasti Pharma (Acasti Pharma Stock Quote, Chart, News NASDAQ:ACST) has a boatload of commercial potential in its omega-3 fatty acid … [Read more...] about Acasti Pharma could have a winner on its hands, says Encode Ideas

Does Acasti Pharma still have upside? Echelon Wealth Partners analyst Douglas Loe could be forgiven for picking up his ball and going home, seeing … [Read more...] about Acasti Pharma still has more upside, Echelon Wealth says

With its best-in-class omega-3 drug CaPre currently in Phase III trials, Acasti Pharma (Acasti Pharma News, Stock Quote, Chart TSXV:ACST) is ready for … [Read more...] about Acasti Pharma: Time to hop on board, says Mackie Research

Echelon Wealth Partners analyst Douglas Loe is staying put on drug developer Acasti Pharma (Acasti Pharma Stock Quote, Chart TSXV:ACST) after the … [Read more...] about Acasti Pharma has a 113 per cent upside, says Echelon Wealth

Acasti Pharma’s (Acasti Pharma Stock Quote, Chart TSXV:ACST) third quarter results are in, but they’re of little consequence at the moment, says … [Read more...] about Acasti Pharma has tonnes of upside, Mackie Research says

Results from a recent study of an omega-3 drug used to treat cardiovascular disease should increase prescriptions of OMG3s in the US, says Mackie … [Read more...] about Acasti Pharma has a potential blockbuster drug on its hands, Mackie Research says